15-min delayed · Sep 9, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 3 firms covering Aurinia Pharmaceuticals Inc, 1 rate it Buy or better, 2 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets are tightly clustered, $16.00 to $21.00, so the covering firms are broadly aligned. The average target of $17.67 sits 9% above the current $16.25. The rating mix has stayed broadly stable, with Buy-side ratings easing from 2 to 1 over recent months. On the fundamentals, the Street sees revenue growth near 15% this year and 18% next, consensus EPS building from about $0.20 next quarter toward $1.07 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS3 ratings
Moderate Buy
Strong Buy00%
Buy133%
Hold267%
Sell00%
Strong Sell00%
Based on 3 analysts giving stock ratings to Aurinia Pharmaceuticals Inc.
As of Sep, 1 of 3 firms rate AUPH a Buy (2 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
AUPH EPS & revenue forecast
EPS · NEXT QUARTER
$0.20
Range $0.16 – $0.25 · 5 analysts · -87% YoY
Next period, 5 analysts expect Aurinia Pharmaceuticals Inc to earn $0.20 a share (range $0.16 – $0.25), versus $1.53 a year earlier. Full-year consensus is $0.94, growing to $1.07 the year after.
REVENUE · NEXT QUARTER
$85.4M
Range $83.2M – $88.3M · 5 analysts · +12% YoY
Revenue is expected to reach $85.4M (range $83.2M – $88.3M), +12.0% year-over-year. Full-year consensus is $329.1M, rising to $384.4M next year.
Top analysts covering Aurinia Pharmaceuticals Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on AUPH.
#1
Arthur He
HC Wainwright & Co. · Rank #157
Buy
$17.00+4.6% to target
Overall win rate
50%
+ Follow
#2
DM
Douglas Miehm
RBC Capital · Rank #190
Hold
$16.00-1.5% to target
Overall win rate
43%
+ Follow
#3
Joseph Schwartz
Leerink Partners
Hold
$16.00-1.5% to target
Coverage
—
+ Follow
#4
MR
Maury Raycroft
Jefferies
Buy
$21.00+29.2% to target
Coverage
—
+ Follow
#5
OB
Olivia Brayer
Cantor Fitzgerald
Buy
$10.00-38.5% to target
Coverage
—
+ Follow
AUPH stock forecast FAQ
What is AUPH's average 12-month price target?+
The 3 analysts with a live target average $17.67 for Aurinia Pharmaceuticals Inc over the next 12 months, ranging from a $21.00 high to a $16.00 low.
Is AUPH stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 3 analyst ratings, 1 are Buy or Strong Buy, 2 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for AUPH?+
The Street-high target is $21.00 (Jefferies), and the Street-low is $16.00 (RBC Capital). The average of all 3 active targets is $17.67.
How many Wall Street analysts cover AUPH?+
3 analysts have an active rating on Aurinia Pharmaceuticals Inc, and 3 firms carry a live 12-month price target.
Who is the most accurate analyst covering AUPH?+
Among analysts who currently cover AUPH, Arthur He of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #157). Their current call is Buy with a $17.00 target.
What is Aurinia Pharmaceuticals Inc's projected EPS for next quarter?+
The consensus estimate is $0.20 per share (range $0.16 – $0.25) across 5 analysts. Full-year EPS is projected at $0.94, rising to $1.07 the following year.
How much revenue is Aurinia Pharmaceuticals Inc expected to report next quarter?+
Consensus revenue is $85.4M (range $83.2M – $88.3M). Full-year revenue is projected at $329.1M, growing to $384.4M next year.
Have analysts been upgrading or downgrading AUPH lately?+
As of Sep, 1 of 3 firms rate AUPH a Buy (2 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their AUPH calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
